Early Experience of Vascular Endothelial Growth Factor (VEGF) Inhibitor in COVID-19 ARDS

Abstract

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

The potential link between Covid‐19 and multiple myeloma: A new saga

“… 48 Therefore, VEGF inhibitors like bevacizumab could be of therapeutic benefit in managing ARDS in Covid‐19. 48 Indeed, HIF‐1 is upregulated in severe Covid‐19 due to hypoxia, and could be a compensatory mechanism to protect tissue against hypoxia. 49 Thus, HIF‐1 stabilizers may prevent Covid‐19 complications and poor clinical outcomes.…”

“…Further, VEGF induces lung inflammation by increasing capillary permeability and plasma extravasation 48 . Therefore, VEGF inhibitors like bevacizumab could be of therapeutic benefit in managing ARDS in Covid‐19 48 . Indeed, HIF‐1 is upregulated in severe Covid‐19 due to hypoxia, and could be a compensatory mechanism to protect tissue against hypoxia 49 .…”

“…Hypoxia in Covid‐19 due to the development of ARDS triggers the release of HIF‐1, which in turn increases the expression of VEGF. Further, VEGF induces lung inflammation by increasing capillary permeability and plasma extravasation 48 . Therefore, VEGF inhibitors like bevacizumab could be of therapeutic benefit in managing ARDS in Covid‐19 48 .…”